Westend Capital Management’s Gilead Sciences GILD Stock Holding History

Westend Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$287K	Hold	2,271	–	–	0.07%	49
2026 Q1	$317K	Hold	2,271	–	–	0.1%	40
2025 Q4	$279K	Hold	2,271	–	–	0.08%	39
2025 Q3	$252K	Hold	2,271	–	–	0.07%	36
2025 Q2	$252K	Sell	2,271 -139,795	-98%	-$14.9M	0.08%	38
2025 Q1	$15.9M	Buy	142,066 +3,424	+2%	+$353K	6.05%	4
2024 Q4	$12.8M	Buy	138,642 +57,632	+71%	+$5.19M	3.8%	11
2024 Q3	$6.79M	Buy	+81,010	New	+$6.18M	2.33%	20

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Westend Capital Management's GILD Position: Q2 2026 in Review

Westend Capital Management held its Gilead Sciences (GILD) position steady in Q2 2026 at 2,271 shares worth $287K. The position accounts for 0.07% of the portfolio, ranked #49.

Westend Capital Management first reported a position in GILD in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.9M in Q1 2025. 2,279 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Westend Capital Management held 2,271 shares of Gilead Sciences worth $287K as of Q2 2026.
Westend Capital Management left its Gilead Sciences share count unchanged in Q2 2026.
Gilead Sciences made up 0.07% of Westend Capital Management's portfolio in Q2 2026, its #49 holding.
Westend Capital Management first reported a position in Gilead Sciences in Q3 2024 and has held it in 8 quarters since.
Westend Capital Management's Gilead Sciences position peaked at $15.9M in Q1 2025.
2,279 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Westend Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.